share_log

Weak Statutory Earnings May Not Tell The Whole Story For Baolingbao BiologyLtd (SZSE:002286)

Weak Statutory Earnings May Not Tell The Whole Story For Baolingbao BiologyLtd (SZSE:002286)

疲軟的法定收入可能無法說明寶靈寶生物有限公司(深圳證券交易所:002286)的全部情況
Simply Wall St ·  05/06 02:57

The subdued market reaction suggests that Baolingbao Biology Co.,Ltd.'s (SZSE:002286) recent earnings didn't contain any surprises. Our analysis suggests that along with soft profit numbers, investors should be aware of some other underlying weaknesses in the numbers.

保齡寶業務的市場反應較爲平淡,表明其最近的收益沒有出現任何驚喜。我們的分析表明,除了收益軟弱之外,投資者還應該注意到數字中的其他潛在弱點。

earnings-and-revenue-history
SZSE:002286 Earnings and Revenue History May 6th 2024
SZSE:002286收益和營業收入歷史 2024年5月6日

How Do Unusual Items Influence Profit?

非常規項目如何影響利潤?

To properly understand Baolingbao BiologyLtd's profit results, we need to consider the CN¥24m gain attributed to unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. We can see that Baolingbao BiologyLtd's positive unusual items were quite significant relative to its profit in the year to March 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

爲了更好地理解保齡寶業務的收益結果,我們需要考慮到歸屬於不尋常項目的2400萬元人民幣收益。雖然收益大幅增加總是令人高興的,但不尋常項目對於增收貢獻的大幅影響有時會削弱我們的熱情。當我們分析了全球絕大部分上市公司時,我們發現重要的不尋常項目往往不會重複出現,這正是會計術語所暗示的。我們可以看到,相對於2024年3月的收益,保齡寶業務的正向不尋常項目相當顯著。其他條件相等的情況下,這很可能會導致公司的盈利能力指數不足,無法成爲公司潛在盈利的良好指南。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Baolingbao BiologyLtd.

注意:我們始終建議投資者查看資產負債表強度。點擊此處可進入關於保齡寶業務資產負債表的分析。

Our Take On Baolingbao BiologyLtd's Profit Performance

我們對保齡寶業務的盈利表現的看法如下

As we discussed above, we think the significant positive unusual item makes Baolingbao BiologyLtd's earnings a poor guide to its underlying profitability. As a result, we think it may well be the case that Baolingbao BiologyLtd's underlying earnings power is lower than its statutory profit. But at least holders can take some solace from the 37% per annum growth in EPS for the last three. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you'd like to know more about Baolingbao BiologyLtd as a business, it's important to be aware of any risks it's facing. For example - Baolingbao BiologyLtd has 3 warning signs we think you should be aware of.

正如我們上面所討論的,我們認爲重要的正向不尋常項目使保齡寶業務的盈利指南不足以反映其潛在的盈利能力。因此,我們認爲,很可能情況是,保齡寶業務的潛在盈利能力低於其法定盈利。但至少持有者可以從過去三年37%的每股收益的增長中獲得一些慰藉。當然,在分析公司的收益時,我們只是刮掉表面而已,還可以考慮利潤率、預測增長和投資回報率等其他因素。如果您想更多地了解保齡寶業務,重要的是要知道它所面臨的任何風險。例如,保齡寶業務有3個我們認爲您應該注意的警告信號。

Today we've zoomed in on a single data point to better understand the nature of Baolingbao BiologyLtd's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

今天我們聚焦了一個單一的數據點,以更好地了解保齡寶業務的盈利性質。但是,還有很多其他方法可以了解公司的情況。有些人認爲高股本回報率是一個優質企業的好跡象。雖然您可能需要進行一些研究,但您可能會發現這個由高股本回報率企業組成的免費收藏,或者這個由內部人士購買的股票列表很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論